- Home
- RGA vs INCY Comparison
RGA vs INCY Comparison
Compare RGA & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGA
- INCY
- Stock Information
- Founded
- RGA 1973
- INCY 1991
- Country
- RGA United States
- INCY United States
- Employees
- RGA N/A
- INCY N/A
- Industry
- RGA Life Insurance
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- RGA Finance
- INCY Health Care
- Exchange
- RGA Nasdaq
- INCY Nasdaq
- Market Cap
- RGA 12.7B
- INCY 13.4B
- IPO Year
- RGA 1993
- INCY 1993
- Fundamental
- Price
- RGA $204.94
- INCY $58.98
- Analyst Decision
- RGA Buy
- INCY Hold
- Analyst Count
- RGA 14
- INCY 20
- Target Price
- RGA $231.00
- INCY $73.06
- AVG Volume (30 Days)
- RGA 405.6K
- INCY 1.8M
- Earning Date
- RGA 05-01-2025
- INCY 04-29-2025
- Dividend Yield
- RGA 1.74%
- INCY N/A
- EPS Growth
- RGA N/A
- INCY N/A
- EPS
- RGA 11.84
- INCY 0.10
- Revenue
- RGA $21,030,000,000.00
- INCY $4,413,226,000.00
- Revenue This Year
- RGA $7.59
- INCY $12.28
- Revenue Next Year
- RGA $10.57
- INCY $9.20
- P/E Ratio
- RGA $17.31
- INCY $611.49
- Revenue Growth
- RGA 1.82
- INCY 17.13
- 52 Week Low
- RGA $159.25
- INCY $52.81
- 52 Week High
- RGA $233.81
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- RGA 64.71
- INCY 44.09
- Support Level
- RGA $193.08
- INCY $57.77
- Resistance Level
- RGA $208.03
- INCY $62.87
- Average True Range (ATR)
- RGA 5.14
- INCY 1.78
- MACD
- RGA 2.17
- INCY 0.20
- Stochastic Oscillator
- RGA 88.34
- INCY 36.23
About RGA Reinsurance Group of America Incorporated
Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.